Pharmacia Axert
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA issues "approvable" letter for the migraine treatment almotriptan Dec. 20. The NDA for the selective serotonin 5-HT receptor agonist was submitted Dec. 17, 1999